This company has been marked as potentially delisted and may not be actively trading. Vermillion (VRML) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VRML vs. VNRX, MYMD, NAVB, ELUT, DOMH, IGMS, AVTE, CELU, NTRB, and QNTMShould you be buying Vermillion stock or one of its competitors? The main competitors of Vermillion include VolitionRx (VNRX), MyMD Pharmaceuticals (MYMD), Navidea Biopharmaceuticals (NAVB), Elutia (ELUT), Dominari (DOMH), IGM Biosciences (IGMS), Aerovate Therapeutics (AVTE), Celularity (CELU), Nutriband (NTRB), and Quantum Biopharma (QNTM). These companies are all part of the "medical" sector. Vermillion vs. Its Competitors VolitionRx MyMD Pharmaceuticals Navidea Biopharmaceuticals Elutia Dominari IGM Biosciences Aerovate Therapeutics Celularity Nutriband Quantum Biopharma Vermillion (NASDAQ:VRML) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment. Which has more volatility & risk, VRML or VNRX? Vermillion has a beta of 3.47, suggesting that its share price is 247% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Which has stronger valuation & earnings, VRML or VNRX? Vermillion has higher revenue and earnings than VolitionRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVermillion$4.54M5.54-$15.24MN/AN/AVolitionRx$1.31M55.23-$35.32M-$0.27-2.57 Is VRML or VNRX more profitable? Vermillion has a net margin of -307.31% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Vermillion's return on equity.Company Net Margins Return on Equity Return on Assets Vermillion-307.31% -155.25% -103.47% VolitionRx -2,321.14%N/A -163.39% Do analysts rate VRML or VNRX? VolitionRx has a consensus price target of $3.50, indicating a potential upside of 403.67%. Given VolitionRx's stronger consensus rating and higher possible upside, analysts clearly believe VolitionRx is more favorable than Vermillion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vermillion 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to VRML or VNRX? In the previous week, VolitionRx had 5 more articles in the media than Vermillion. MarketBeat recorded 5 mentions for VolitionRx and 0 mentions for Vermillion. Vermillion's average media sentiment score of 0.00 beat VolitionRx's score of -0.02 indicating that Vermillion is being referred to more favorably in the media. Company Overall Sentiment Vermillion Neutral VolitionRx Neutral Do insiders and institutionals believe in VRML or VNRX? 18.1% of Vermillion shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 4.4% of Vermillion shares are owned by company insiders. Comparatively, 10.4% of VolitionRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryVermillion and VolitionRx tied by winning 8 of the 16 factors compared between the two stocks. Get Vermillion News Delivered to You Automatically Sign up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRML vs. The Competition Export to ExcelMetricVermillionDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.14M$18.48M$5.69B$9.81BDividend YieldN/AN/A3.79%4.07%P/E Ratio-1.52N/A31.0525.11Price / Sales5.5420.57466.03115.19Price / CashN/AN/A37.4059.05Price / Book2.870.019.096.18Net Income-$15.24M-$15.34M$3.26B$265.11M Vermillion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRMLVermillionN/A$0.26+7.6%N/A-78.2%$25.14M$4.54M-1.5243VNRXVolitionRx2.2078 of 5 stars$0.62flat$3.50+464.5%+21.9%$64.47M$1.31M-1.7280News CoverageAnalyst ForecastGap UpMYMDMyMD PharmaceuticalsN/A$0.11+13.5%N/A-94.3%$260KN/A0.006Gap DownHigh Trading VolumeNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$50K$8.13K0.0010ELUTElutia3.6446 of 5 stars$1.99+1.0%$8.00+302.0%-39.9%$81M$24.38M-1.03180News CoverageEarnings ReportDOMHDominari0.5607 of 5 stars$6.67+25.1%N/A+278.7%$78.05M$18.15M-2.814News CoverageEarnings ReportAnalyst UpgradeHigh Trading VolumeIGMSIGM Biosciences4.5918 of 5 stars$1.30+0.8%$5.50+323.1%N/A$77.78M$2.68M-1.44190News CoverageAnalyst UpgradeAVTEAerovate TherapeuticsN/A$7.40-1.2%N/A-89.2%$77.68MN/A-2.4720High Trading VolumeCELUCelularity0.4299 of 5 stars$3.06-5.3%N/A+18.0%$77.36M$54.22M-1.15220NTRBNutriband3.2603 of 5 stars$6.80-0.7%$13.00+91.2%+7.5%$76.41M$2.14M-7.5610Short Interest ↓Gap DownQNTMQuantum BiopharmaN/A$24.33-7.3%N/AN/A$76.35MN/A-1.74N/AHigh Trading Volume Related Companies and Tools Related Companies VolitionRx Competitors MyMD Pharmaceuticals Competitors Navidea Biopharmaceuticals Competitors Elutia Competitors Dominari Competitors IGM Biosciences Competitors Aerovate Therapeutics Competitors Celularity Competitors Nutriband Competitors Quantum Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRML) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Debt Crisis Is Coming—Will You Be Ready?A full-blown "economic heart attack" is coming—and the markets aren't ready. The problem? Exploding U.S. de...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vermillion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vermillion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access